However, we found that tumor mutation burden and predicted neoantigen counts were equivalent in BRCA1-deficient and BRCA2-deficient tumors between STS and LTS groups (Fig. 4a-c, Extended Data Fig. 5a, and Supplementary Table S19). The gene discussed is BRCA2; the disease is neoplasm.